{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:14:46Z","timestamp":1793272486950,"version":"4.5.0"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11102-017-0797-7","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T10:33:31Z","timestamp":1487673211000},"page":"46-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":199,"title":["Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-1348","authenticated-orcid":false,"given":"Rosario","family":"Pivonello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata S.","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica F. S.","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Simeoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Patalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Galdiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"797_CR1","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","volume":"94","author":"S Melmed","year":"2009","unstructured":"Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleimberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509\u20131517","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1210\/er.2003-0009","volume":"24","author":"RN Clayton","year":"2003","unstructured":"Clayton RN (2003) Cardiovascular function in acromegaly. Endocr Rev 24:272\u2013274","journal-title":"Endocr Rev"},{"key":"797_CR3","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","volume":"355","author":"S Melmed","year":"2006","unstructured":"Melmed S (2006) Medical progress: acromegaly. New Engl J Med 355:2558\u20132573","journal-title":"New Engl J Med"},{"key":"797_CR4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","volume":"25","author":"A Colao","year":"2004","unstructured":"Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 25:102\u2013152","journal-title":"Endocr Rev"},{"key":"797_CR5","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0002-9149(99)80721-8","volume":"75","author":"A Giustina","year":"1995","unstructured":"Giustina A, Boni E, Romanelli G, Grassi V, Giustina G (1995) Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 75:1042\u20131047","journal-title":"Am J Cardiol"},{"issue":"2","key":"797_CR6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","volume":"89","author":"IM Holdaway","year":"2004","unstructured":"Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667\u2013674","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"797_CR7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1530\/ERC-16-0106","volume":"23","author":"E Ritvonen","year":"2015","unstructured":"Ritvonen E, L\u00f6yttyniemi E, Jaatinen P, Ebeling T, Moilanen L, Nuutila P, Kauppinen-M\u00e4kelin R, Schalin-J\u00e4ntti C (2015) Mortality in acromegaly: a 20-year follow-up study. Endocr Relat Cancer 23(6):469\u2013480","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"797_CR8","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2014-2670","volume":"99","author":"M Mercado","year":"2014","unstructured":"Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, Jervis P, Roldan P, Mendoza V, L\u00f3pez-F\u00e9lix B, Guinto G (2014) Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 99(12):4438\u20134446","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"797_CR9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/oxfordjournals.eurheartj.a060047","volume":"13","author":"G Kahaly","year":"1992","unstructured":"Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, Meyer J (1992) Arrhythmia profile in acromegaly. Eur Heart J 13(1):51\u201356","journal-title":"Eur Heart J"},{"issue":"7","key":"797_CR10","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1210\/jc.2002-021099","volume":"88","author":"A Colao","year":"2003","unstructured":"Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi, G (2003) High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 88(7):3196\u20133201","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2265.1980.tb03135.x","volume":"12","author":"L Alexander","year":"1980","unstructured":"Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 12:71\u201379","journal-title":"Clin Endocrinol"},{"key":"797_CR12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2265.1987.tb00805.x","volume":"26","author":"JDN Nabarro","year":"1987","unstructured":"Nabarro JDN (1987) Acromegaly. Clin Endocrinol 26:481\u2013512","journal-title":"Clin Endocrinol"},{"key":"797_CR13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.0954-6820.1988.tb15881.x","volume":"223","author":"BA Bengtsson","year":"1988","unstructured":"Bengtsson BA, Eden S, Ernest I, Oden A, Sj\u00f6gren B (1988) Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223:327\u2013335","journal-title":"Acta Med Scand"},{"issue":"4","key":"797_CR14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11102-011-0365-5","volume":"15","author":"C Giordano","year":"2012","unstructured":"Giordano C, Ciresi A, Amato MC et al (2012) Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 15(4):539\u2013551","journal-title":"Pituitary"},{"key":"797_CR15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1590\/S0100-879X2001001100009","volume":"34","author":"A Kreze","year":"2001","unstructured":"Kreze A, Kreze-Spirova E, Mikulecky M (2001) Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 34:1429\u20131433","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"797_CR16","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.1210\/jc.2012-2896","volume":"98","author":"A Ciresi","year":"2013","unstructured":"Ciresi A, Amato MC, Pivonello R et al (2013) The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 98(1):E51\u2013E59","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"797_CR17","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1210\/jc.2008-0299","volume":"93","author":"A Colao","year":"2008","unstructured":"Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G (2008) Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 93(7):2639\u20132646","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2265.2003.01689.x","volume":"58","author":"A Colao","year":"2003","unstructured":"Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G (2003) Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol 58:169\u2013176","journal-title":"Clin Endocrinol"},{"key":"797_CR19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11102-010-0284-x","volume":"14","author":"AL Espinosa-de-los-Monteros","year":"2011","unstructured":"Espinosa-de-los-Monteros AL, Gonz\u00e1lez B, Vargas G et al (2011) Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 14:231\u2013235","journal-title":"Pituitary"},{"issue":"11","key":"797_CR20","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1210\/jc.2016-1937","volume":"101","author":"LA Portocarrero-Ortiz","year":"2016","unstructured":"Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M et al (2016) The Mexican Acromegaly Registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab 101(11):3997\u20134004","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2265.2000.00986.x","volume":"52","author":"S Kasayama","year":"2000","unstructured":"Kasayama S, Otsuki M, Takagi M et al (2000) Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol 52:549\u2013555","journal-title":"Clin Endocrinol"},{"issue":"6","key":"797_CR22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/EJE-10-1050","volume":"164","author":"S Fieffe","year":"2011","unstructured":"Fieffe S, Morange I, Petrossians P et al (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164(6):877\u2013884","journal-title":"Eur J Endocrinol"},{"key":"797_CR23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2265.2001.01218.x","volume":"54","author":"A Colao","year":"2001","unstructured":"Colao A, Marzullo P, Di Somma C, Lombardi, G (2001) Growth hormone and the heart. Clin Endocrinol 54:137\u2013154","journal-title":"Clin Endocrinol"},{"key":"797_CR24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/s-2007-978698","volume":"31","author":"J Isgaard","year":"1999","unstructured":"Isgaard J, Tivesten A, Friberg P, Bengtsson BA (1999) The role of the GH\/IGF-I axis for the cardiac function and structure. Horm Metab Res 31:50\u201354","journal-title":"Horm Metab Res"},{"key":"797_CR25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1677\/joe.0.1200107","volume":"120","author":"J Isgaard","year":"1989","unstructured":"Isgaard J, Nilsson A, Vickman K, Isaksson, OGP (1989) Growth hormone regulates the level of insulin-like growth factor-ImRNAin rats skeletal muscle. J Endocrinol 120:107\u2013112","journal-title":"J Endocrinol"},{"key":"797_CR26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0008-6363(95)00163-8","volume":"30","author":"P Delafontaine","year":"1995","unstructured":"Delafontaine P (1995) Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 30:825\u2013834","journal-title":"Cardiovasc Res"},{"key":"797_CR27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1126\/science.3563497","volume":"236","author":"VK Han","year":"1987","unstructured":"Han VK, D\u2019Ercole AJ, Lund PK (1987) Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 236:193\u2013197","journal-title":"Science"},{"key":"797_CR28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1161\/01.CIR.93.4.800","volume":"93","author":"A Cittadini","year":"1996","unstructured":"Cittadini A, Stromer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS (1996) Differential cardiac effects of growth hormone and insulin-like growth factor-I in the rat. A combined in vivo and in vitro evaluation. Circulation 93:800\u2013809","journal-title":"Circulation"},{"key":"797_CR29","doi-asserted-by":"crossref","first-page":"22892","DOI":"10.1074\/jbc.M011647200","volume":"276","author":"C Lu","year":"2001","unstructured":"Lu C, Schwartzbauer G, Sperling MA, Devaskar SU, Thamotharan S, Robbins PD, McTiernan CF, Liu JL, Jiang J, Frank SJ, Menon RK (2001) Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem 276:22892\u201322900","journal-title":"J Biol Chem"},{"key":"797_CR30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/BF01906959","volume":"83","author":"U Vetter","year":"1988","unstructured":"Vetter U, Kupferschmid C, Lang D, Pents S (1988) Insulin-like growth factors and insulin increase the contractility of neonatal rat cardiocytes in vitro. Basic Res Cardiol 83:647\u2013654","journal-title":"Basic Res Cardiol"},{"issue":"3","key":"797_CR31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cardiores.2007.06.026","volume":"76","author":"A Br\u00fcel","year":"2007","unstructured":"Br\u00fcel A, Christoffersen TE, Nyengaard JR (2007) Growth hormone increases the proliferation of existing cardiac myocytes and the total number of cardiac myocytes in the rat heart. Cardiovasc Res 76(3):400\u2013408","journal-title":"Cardiovasc Res"},{"key":"797_CR32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0954-6820.1988.tb15882.x","volume":"223","author":"L Thuesen","year":"1988","unstructured":"Thuesen L, Christensen SE, Weeke J, Orskov H, Henningsen P (1988) A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients? Acta Med Scand 223:337\u2013343","journal-title":"Acta Med Scand"},{"issue":"4","key":"797_CR33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1020750514954","volume":"4","author":"G Vitale","year":"2001","unstructured":"Vitale G, Pivonello R, Galderisi M, D\u2019Errico A, Spinelli L, Lupoli G, Lombardi G, Colao A (2001) Cardiovascular complications in acromegaly: methods of assessment. Pituitary 4(4):251\u2013257","journal-title":"Pituitary"},{"key":"797_CR34","first-page":"S33","volume":"155","author":"G Lombardi","year":"1997","unstructured":"Lombardi G, Colao A, Marzullo P, Ferone D, Longobardi S, Esposito V, Merola B (1997) Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. J Endocrinol 155:S33","journal-title":"J Endocrinol"},{"key":"797_CR35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archinte.1938.00180100014002","volume":"61","author":"C Courville","year":"1938","unstructured":"Courville C, Mason VR (1938) The heart in acromegaly. Arch Int Med 61:704","journal-title":"Arch Int Med"},{"key":"797_CR36","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.7326\/0003-4819-34-6-1445","volume":"34","author":"MR Hejtmancik","year":"1951","unstructured":"Hejtmancik MR, Bradfield JY, Herrmann GR (1951) Acromegaly and the heart: a clinical and pathologic study. Ann Intern Med 34:1445","journal-title":"Ann Intern Med"},{"key":"797_CR37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-8703(80)90277-X","volume":"100","author":"JT Lie","year":"1980","unstructured":"Lie JT, Grossman SJ (1980) Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 100:41","journal-title":"Am Heart J"},{"key":"797_CR38","first-page":"41","volume":"62","author":"RP Hayward","year":"1987","unstructured":"Hayward RP, Emanuel RW, Nabarro, J.D.N. (1987) Acromegalic heart disease: influence of treatment of the acromegaly on the heart. Q J Med 62:41","journal-title":"Q J Med"},{"issue":"3","key":"797_CR39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2265.2007.03047.x","volume":"68","author":"F Bogazzi","year":"2008","unstructured":"Bogazzi F, Lombardi M, Strata E, Aquaro G, Di Bello V, Cosci C, Sardella C, Talini E, Martino E (2008) High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin Endocrinol 68(3):361\u2013368","journal-title":"Clin Endocrinol"},{"issue":"12","key":"797_CR40","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1210\/jc.2015-2675","volume":"100","author":"CM Santos Silva dos","year":"2015","unstructured":"dos Santos Silva CM, Gottlieb I, Volschan I, Kasuki L, Warszawski L, Balarini Lima GA, Xavier SS, Pedrosa RC, Neto LV, Gadelha MR (2015) Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort. J Clin Endocrinol Metab 100(12):4447\u20134455","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR41","first-page":"193","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193\u2013199","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"797_CR42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1020798430884","volume":"4","author":"M Bondanelli","year":"2001","unstructured":"Bondanelli M, Ambrosio MR, degli Uberti EC (2001) Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 4(4):239\u2013249","journal-title":"Pituitary"},{"key":"797_CR43","first-page":"423","volume":"5","author":"S Feld","year":"1996","unstructured":"Feld S, Hirschgerg R (1996) Growth Hormone, the insulin-like growth factor system, and the kidney. J Clin Endocrinol Metab 5:423\u2013480","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"797_CR44","doi-asserted-by":"crossref","first-page":"E1326","DOI":"10.1152\/ajpendo.2001.281.6.E1326","volume":"281","author":"TK Hansen","year":"2001","unstructured":"Hansen TK, M\u00f8ller J, Thomsen K, Frandsen E, Dall R, J\u00f8rgensen JO, Christiansen JS (2001) Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 281(6):E1326\u2013E1332","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"797_CR45","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1161\/hc4601.099489","volume":"104","author":"E Rabkin","year":"2001","unstructured":"Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ (2001) Activated myofibroblasts express catabolic enzymes and mediate matrix re- modeling in myxomatous heart valves. Circulation 104:2525\u20132253","journal-title":"Circulation"},{"key":"797_CR46","unstructured":"Feelders RA, Savelkoul HF, de Herder WW, Hooijkaas H, Lamberts SW (2002) The cytokine network in acromegaly before and after pituitary surgery: growth hormone excess is associated with a reversible shift to the T-helper 1 cytokine response. Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, CA, p\u00a076 (Abstract OR8-5)"},{"key":"797_CR47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1210\/jc.2003-030849","volume":"89","author":"AM Pereira","year":"2004","unstructured":"Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ (2004) Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 89:71\u201375","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ghir.2006.02.002","volume":"16","author":"AA Klaauw van der","year":"2006","unstructured":"van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, van der Wall EE, Smit JW, Romijn JA, Pereira AM (2006) Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res 16:101\u2013107","journal-title":"Growth Horm IGF Res"},{"issue":"4","key":"797_CR49","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2265.2011.04131.x","volume":"75","author":"A Colao","year":"2011","unstructured":"Colao A, Grasso LF (2011) Aortic root ectasia in patients with acromegaly: an emerging complication. Clin Endocrinol 75(4):420\u2013421","journal-title":"Clin Endocrinol"},{"key":"797_CR50","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2265.2011.04067.x","volume":"75","author":"AF Casini","year":"2011","unstructured":"Casini AF, Neto LV, Fontes R, Fran\u00e7a RF, Xavier SS, Gadelha MR (2011) Aortic root ectasia in patients with acromegaly: experience at a single center. Clin Endocrinol 75:495\u2013500","journal-title":"Clin Endocrinol"},{"key":"797_CR51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-08-0138","volume":"159","author":"AA Klaauw van der","year":"2008","unstructured":"van der Klaauw AA, Bax JJ, Smit JW, Holman ER, Delgado V, Bleeker GB, Biermasz NR, Roelfsema, .F, Romijn JA, Pereira AM (2008) Increased aortic root diameters in patients with acromegaly. Eur J Endocrinol 159:97\u2013103","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"797_CR52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00024677-200403050-00004","volume":"3","author":"G Vitale","year":"2004","unstructured":"Vitale G, Pivonello R, Lombardi G, Colao A (2004) Cardiac abnormalities in acromegaly. Pathophysiology and implications for management. Treat Endocrinol 3(5):309\u2013318","journal-title":"Treat Endocrinol"},{"issue":"6","key":"797_CR53","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11102-016-0749-7","volume":"19","author":"L Warszawski","year":"2016","unstructured":"Warszawski L, Kasuki L, S\u00e1 R, Dos Santos Silva CM, Volschan I, Gottlieb I, Pedrosa RC, Gadelha MR (2016) Low frequency of cardiac arrhythmias and lack of structural heart disease in medically-na\u00efve acromegaly patients: a prospective study at baseline and after 1\u00a0year of somatostatin analogs treatment. Pituitary 19(6):582\u2013589","journal-title":"Pituitary"},{"key":"797_CR54","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12020-012-9859-9","volume":"44","author":"A K\u0131r\u0131\u015f","year":"2013","unstructured":"K\u0131r\u0131\u015f A, Erem C, Turan OE, Civan N, K\u0131r\u0131\u015f G, Nuho\u011flu I, Ilter A, Ers\u00f6z HO, Kutlu M (2013) Left ventricular synchronicity is impaired in patients with active acromegaly. Endocr 44:200\u2013206","journal-title":"Endocr"},{"issue":"5","key":"797_CR55","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1530\/EJE-11-0408","volume":"165","author":"A Colao","year":"2011","unstructured":"Colao A, Pivonello R, Grasso LF, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2011) Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10\u00a0year survey study. Eur J Endocrinol 165(5):713\u2013721","journal-title":"Eur J Endocrinol"},{"key":"797_CR56","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1365-2265.2011.04019.x","volume":"75","author":"C Jayasena","year":"2011","unstructured":"Jayasena C, Comninos A, Clarke H, Donaldson M, Meeran K, Dhillo W (2011) The effects of long term GH and IGF-I exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol 75:220\u2013225","journal-title":"Clin Endocrinol"},{"issue":"2","key":"797_CR57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/CS20050281","volume":"110","author":"IJ Andersson","year":"2006","unstructured":"Andersson IJ, Johansson ME, Wickman A, Bohlooly-Y M, Klintland N, Caidahl K, Gustafsson M, Bor\u00e9n J, Gan LM, Bergstr\u00f6m G (2006) Endothelial dysfunction in growth hormone transgenic mice. Clin Sci 110(2):217\u2013225","journal-title":"Clin Sci"},{"issue":"4","key":"797_CR58","first-page":"314","volume":"45","author":"P Anagnostis","year":"2013","unstructured":"Anagnostis P, Efstathiadou ZA, Gougoura S, Polyzos SA, Karathanasi E, Dritsa P, Kita M, Koukoulis GN (2013) Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly. Horm Metab Res 45(4):314\u2013318","journal-title":"Horm Metab Res"},{"issue":"4","key":"797_CR59","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/08037050510034293","volume":"14","author":"V Ronconi","year":"2005","unstructured":"Ronconi V, Giacchetti G, Mariniello B, Camilletti A, Mantero F, Boscaro M, Vignini A, Mazzanti L (2005) Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Press 14(4):227\u2013232","journal-title":"Blood Press"},{"issue":"7","key":"797_CR60","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1358\/mf.2009.31.7.1415895","volume":"31","author":"G Kirilov","year":"2009","unstructured":"Kirilov G, Zacharieva S, Alexandrov AS, Lozanov V, Mitev V (2009) Increased plasma endothelin level as an endothelial marker of cardiovascular risk in patients with active acromegaly: a comparison with plasma homocysteine. Methods Find Exp Clin Pharmacol 31(7):457\u2013461","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"3","key":"797_CR61","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000204355","volume":"18","author":"M Baykan","year":"2009","unstructured":"Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, Kaplan S, Korkmaz L, Celik S (2009) Impairment in flow-mediated vasodilatation of the brachial artery in acromegaly. Med Princ Pract 18(3):228\u2013232","journal-title":"Med Princ Pract"},{"issue":"4","key":"797_CR62","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1210\/jc.2008-0948","volume":"94","author":"AN Paisley","year":"2009","unstructured":"Paisley AN, Izzard AS, Gemmell I, Cruickshank K, Trainer PJ, Heagerty AM (2009) Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin Endocrinol Metab 94(4):1111\u20131117","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"797_CR63","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/cen.12356","volume":"80","author":"O Topaloglu","year":"2014","unstructured":"Topaloglu O, Sayki Arslan M, Turak O, Ginis Z, Sahin M, Cebeci M, Ucan B, Cakir E, Karbek B, Ozbek M, Cakal E, Delibasi T (2014) Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules. Clin Endocrinol 80(5): 726\u2013734","journal-title":"Clin Endocrinol"},{"key":"797_CR64","first-page":"3151","volume":"84","author":"F Schiavon","year":"1999","unstructured":"Schiavon F, Maffei P, Martini C, De Carlo E, Fais C, Todesco S, Sicolo N (1999) Morphologic study of microcirculation in acromegaly by capillaroscopy. J Clin Endocrinol Metab 84:3151\u20133155","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR65","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1210\/jcem.87.7.8643","volume":"87","author":"G Brevetti","year":"2002","unstructured":"Brevetti G, Marzullo P, Silvestro A, Pivonello R, Oliva G, di Somma C, Lombardi G, Colao A (2002) Early vascular alterations in acromegaly. J Clin Endocrinol Metab 87:3174\u20133179","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR66","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2265.2001.01256.x","volume":"54","author":"A Colao","year":"2001","unstructured":"Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D, Di Somma C, Assanti AP, Lombardi G (2001) Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol 54:515\u2013524","journal-title":"Clin Endocrinol"},{"key":"797_CR67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1742-1241.2008.01750.x","volume":"64","author":"I Kartal","year":"2010","unstructured":"Kartal I, Oflaz H, Pamuk\u00e7u B, Meri\u00e7 M, Aral F, Ozbey N, Alag\u00f6l F (2010) Investigation of early atherosclerotic changes in acromegalic patients. Int J Clin Pract 64:39\u201344","journal-title":"Int J Clin Pract"},{"key":"797_CR68","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1210\/jc.2010-2225","volume":"96","author":"AN Paisley","year":"2011","unstructured":"Paisley AN, Banerjee M, Rezai M, Schofield RE, Balakrishnannair S, Herbert A, Lawrance JA, Trainer PJ, Cruickshank JK (2011) Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J Clin Endocrinol Metab 96:1486\u20131492","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR69","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1210\/jc.2007-1213","volume":"92","author":"F Bogazzi","year":"2007","unstructured":"Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, Cosci C, Sardella C, Volterrani D, Talini E, Pepe P, Falaschi F, Mariani G, Martino, E (2007) Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92:4271\u20134277","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR70","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1530\/EJE-09-0945","volume":"162","author":"H Akutsu","year":"2010","unstructured":"Akutsu H, Kreutzer J, Wasmeier G, Ropers D, Rost C, M\u00f6hlig M, Wallaschofski H, Buchfelder M, Sch\u00f6fl C (2010) Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol 162:879\u2013886","journal-title":"Eur J Endocrinol"},{"key":"797_CR71","first-page":"1551","volume":"86","author":"A Colao","year":"2001","unstructured":"Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Pivonello R, Salvatore M, Lombardi G (2001) Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor levels on cardiac performance. J Clin Endocrinol Metab 86:1551\u20131557","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"797_CR72","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1540-8175.2010.01179.x","volume":"27","author":"E Akgul","year":"2010","unstructured":"Akgul E, Tokgozoglu SL, Erbas T, Kabakci G, Aytemir K, Haznedaroglu I, Oto A, Kes SS (2010) Evaluation of the impact of treatment on endothelial function and cardiac performance in acromegaly. Echocardiography 27(8):990\u2013996","journal-title":"Echocardiography"},{"issue":"5","key":"797_CR73","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1507\/endocrj.K07E-125","volume":"55","author":"H Sakai","year":"2008","unstructured":"Sakai H, Tsuchiya K, Nakayama C, Iwashima F, Izumiyama H, Doi M, Yoshimoto T, Tsujino M, Yamada S, Hirata Y (2008) Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery. Endocr J 55(5):853\u2013859","journal-title":"Endocr J"},{"issue":"10","key":"797_CR74","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2009-0941","volume":"94","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 94(10):3746\u20133756","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"797_CR75","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jc.2012-3072","volume":"98","author":"AK Annamalai","year":"2013","unstructured":"Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, Maki-Petaja K, Gayton EL, Strey CH, O\u2019Toole S, Ariyaratnam S, Halsall DJ, Chaudhry AN, Berman L, Scoffings DJ, Antoun NM, Dutka DP, Wilkinson IB, Shneerson JM, Pickard JD, Simpson HL, Gurnell M (2013) A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 98(3):1040\u20131050","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR76","first-page":"3132","volume":"86","author":"A Colao","year":"2000","unstructured":"Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G (2000) Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 86:3132\u20133140","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR77","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1007\/BF03349164","volume":"26","author":"A Giustina","year":"2003","unstructured":"Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S; The Pituitary Society and the European Neuroendocrine Association (2003) Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242\u20131247","journal-title":"J Endocrinol Invest"},{"key":"797_CR78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/jcem.84.1.5368","volume":"84","author":"A Colao","year":"1999","unstructured":"Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G (1999) Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 84:17\u201323","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"797_CR79","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","volume":"154","author":"A Colao","year":"2006","unstructured":"Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154(3):467\u2013477","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"797_CR80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/EJE-12-0596","volume":"168","author":"RS Auriemma","year":"2012","unstructured":"Auriemma RS, Pivonello R, De Martino MC, Cudemo G, Grasso LF, Galdiero M, Perone Y, Colao, A (2012) Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. Eur J Endocrinol 168(1):15\u201322","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"797_CR81","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/BF03346667","volume":"33","author":"MC Martino De","year":"2010","unstructured":"De Martino MC, Auriemma RS, Brevetti G, Vitale G, Schiano V, Galdiero M, Grasso L, Lombardi G, Colao A, Pivonello R (2010) The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J Endocrinol Invest 33(9):663\u2013670","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"797_CR82","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/jc.2006-1587","volume":"92","author":"R Pivonello","year":"2007","unstructured":"Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, D\u2019Errico A, Kourides I, Burman P, Lombardi G, Colao, A (2007) Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Encocrinol Metab 92(2):476\u2013482","journal-title":"J Clin Encocrinol Metab"},{"key":"797_CR83","doi-asserted-by":"crossref","unstructured":"Auriemma RS, Grasso LF, Galdiero M, Galderisi M, Pivonello C, Simeoli C, De Martino MC, Ferrigno R, Negri M, de Angelis C, Pivonello R, Colao A (2016) Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine (Epub ahead of print)","DOI":"10.1530\/endoabs.37.GP.19.08"},{"key":"797_CR84","first-page":"517","volume":"47","author":"BD Harrison","year":"1978","unstructured":"Harrison BD, Millhouse KA, Harrington M, Nabarro JD (1978) Lung function in acromegaly. Q J Med 47:517\u2013532","journal-title":"Q J Med"},{"key":"797_CR85","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thx.32.3.322","volume":"22","author":"CC Evans","year":"1977","unstructured":"Evans CC, Hipkin LJ, Murray GM (1977) Pulmonary function in acromegaly. Thorax 22:322\u2013327","journal-title":"Thorax"},{"key":"797_CR86","first-page":"527","volume":"79","author":"B Trotman-Dickenson","year":"1991","unstructured":"Trotman-Dickenson B, Weetman AP, Hughes JM (1991) Upper airflow obstruction and pulmonary function in acromegaly: relationship to disease activity. Q J Med 79:527\u2013538","journal-title":"Q J Med"},{"key":"797_CR87","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1164\/arrd.1980.121.3.471","volume":"121","author":"R Luboshitzky","year":"1980","unstructured":"Luboshitzky R, Barzilai D (1980) Hypoxemia and pulmonary function in acromegaly. Am Rev Respir Dis 121:471\u2013475","journal-title":"Am Rev Respir Dis"},{"key":"797_CR88","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1210\/endo.130.5.1374020","volume":"130","author":"PE Lobie","year":"1992","unstructured":"Lobie PE, Garcia-Aragon J, Wang BS, Baumback WR, Waters MJ (1992) Cellular localization of the growth hormone binding protein in the rat. Endocrinology 130:3057\u20133065","journal-title":"Endocrinology"},{"key":"797_CR89","first-page":"775","volume":"81","author":"G Zogopoulos","year":"1996","unstructured":"Zogopoulos G, Figueiredo R, Jenab A, Ali Z, Lefebvre Y, Goodyer CG (1996) Expression of exon 3-retaining and -deleted human growth hormone receptor messenger ribonucleic acid isoforms during development. J Clin Endocrinol Metab 81:775\u2013782","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR90","first-page":"646","volume":"75","author":"DJ Hill","year":"1992","unstructured":"Hill DJ, Riley SC, Bassett NS, Waters MJ (1992) Localization of the growth hormone receptor, identified by immunocytochemistry, in second trimester human fetal tissues and in placenta throughout gestation. J Clin Endocrinol Metab 75:646\u2013650","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR91","doi-asserted-by":"crossref","first-page":"527","DOI":"10.7326\/0003-4819-115-7-527","volume":"115","author":"RR Grunstein","year":"1991","unstructured":"Grunstein RR, Ho KY, Sullivan CE (1991) Sleep apnea in acromegaly. Ann Intern Med 115:527\u2013532","journal-title":"Ann Intern Med"},{"key":"797_CR92","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1172\/JCI113781","volume":"82","author":"WN Rom","year":"1988","unstructured":"Rom WN, Basset P, Fells GA, Nukiwa T, Trapnell BC, Crystal RG (1988) Alveolar macrophages release an insulin-like growth factor I-type molecule. J Clin Invest 82:1685\u20131693","journal-title":"J Clin Invest"},{"issue":"10","key":"797_CR93","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1590\/1414-431X20154786","volume":"48","author":"GB Camilo","year":"2015","unstructured":"Camilo GB, Carvalho AR, Machado DC, Mogami R, Kasuki L, Gadelha MR, Melo PL, Lopes AJ (2015) Correlations between forced oscillation technique parameters and pulmonary densitovolumetry values in patients with acromegaly. Braz J Med Biol Res 48(10):877\u2013885","journal-title":"Braz J Med Biol Res"},{"key":"797_CR94","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1164\/ajrccm.164.5.2005059","volume":"164","author":"F Garcia-Rio","year":"2001","unstructured":"Garcia-Rio F, Pino JM, Diez JJ, Ruiz A, Villasante C, Villamor J (2001) Reduction of lung distensibility in acromegaly after suppression of growth hormone hypersecretion. Am J Respir Crit Care Med 164:852\u2013857","journal-title":"Am J Respir Crit Care Med"},{"key":"797_CR95","first-page":"L761","volume":"267","author":"JP Noveral","year":"1994","unstructured":"Noveral JP, Bhala A, Hintz RL, Grunstein MM, Cohen P (1994) Insulin-like growth factor axis in airway smooth muscle cells. Am J Physiol 267:L761\u2013L765","journal-title":"Am J Physiol"},{"key":"797_CR96","first-page":"L276","volume":"263","author":"CB Rich","year":"1992","unstructured":"Rich CB, Ewton DZ, Martin BM, Florini JR, Bashir M, Rosenbloom J, Foster JA (1992) IGF-I regulation of elastogenesis: comparison of aortic and lung cells. Am J Physiol 263:L276\u2013L282","journal-title":"Am J Physiol"},{"key":"797_CR97","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF03343767","volume":"23","author":"V Weiss","year":"2000","unstructured":"Weiss V, Sonka K, Pretl M, Dostalova S, Klozar J, Rambousek P, Marek J, Haas T (2000) Prevalence of the sleep apnea syndrome in acromegaly population. J Endocrinol Invest 23:515\u2013519","journal-title":"J Endocrinol Invest"},{"key":"797_CR98","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/eje.0.1440491","volume":"144","author":"S Dostalova","year":"2001","unstructured":"Dostalova S, Sonka K, Smahel Z, Weiss V, Marek J, Horinek D (2001) Craniofacial abnormalities and their relevance for sleep apnea syndrome aetiopathogenesis in acromegaly. Eur J Endocrinol 144:491\u2013497","journal-title":"Eur J Endocrinol"},{"key":"797_CR99","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2265.2001.01358.x","volume":"55","author":"MSM Ip","year":"2001","unstructured":"Ip, MSM, Tan KCB, Peh WCG, Lam KSL (2001) Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol 55:477\u2013483","journal-title":"Clin Endocrinol"},{"issue":"8","key":"797_CR100","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1210\/jc.2013-4288","volume":"99","author":"D Chemla","year":"2014","unstructured":"Chemla D, Attal P, Maione L, Veyer AS, Mroue G, Baud D, Salenave S, Kamenicky P, Bobin S, Chanson P (2014) Impact of successful treatment of acromegaly on overnight heart rate variability and sleep apnea. J Clin Endocrinol Metab 99(8):2925\u20132931","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR101","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/ajrccm.160.1.9806054","volume":"160","author":"S Isono","year":"1999","unstructured":"Isono S, Saeki N, Tanaka A, Nishino T (1999) Collapsibility of passive pharynx in patients with acromegaly. Am J Respir Crit Care Med 160:64\u201368","journal-title":"Am J Respir Crit Care Med"},{"key":"797_CR102","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0009-9260(86)80327-0","volume":"37","author":"DJ Morewood","year":"1986","unstructured":"Morewood DJ, Belchetz PE, Evans CC, Whitehouse GH (1986) The extrathoracic airway in acromegaly. Clin Radiol 37:243\u2013246","journal-title":"Clin Radiol"},{"key":"797_CR103","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/bmj.280.6218.894","volume":"280","author":"WH Perks","year":"1980","unstructured":"Perks WH, Horrocks PM, Cooper RA, Bradbury S, Allen A, Baldock N, Prowse K, van\u2019t Hoff W (1980) Sleep apnoea in acromegaly. Br Med J 280:894\u2013897","journal-title":"Br Med J"},{"key":"797_CR104","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archinte.1985.00360050121021","volume":"145","author":"TB Hart","year":"1985","unstructured":"Hart TB, Radow SK, Blackard WG, Tucker HS, Cooper KR (1985) Sleep apnea in active acromegaly. Arch Intern Med 145:865\u2013866","journal-title":"Arch Intern Med"},{"key":"797_CR105","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1183\/09031936.97.10050977","volume":"10","author":"I Iandelli","year":"1997","unstructured":"Iandelli I, Gorini M, Duranti R, Bassi F, Misuri G, Pacini F, Rosi E, Scano G (1997) Respiratory muscle function and control of breathing in patients with acromegaly. Eur Respir J 10:977\u2013982","journal-title":"Eur Respir J"},{"key":"797_CR106","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jcem.87.7.8573","volume":"87","author":"A Colao","year":"2002","unstructured":"Colao A, Spinelli L, Cuocolo A, Spiezia S, Bonaduce D, Salvatore M, Lombardi G (2002) Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 87:3097\u20133104","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR107","first-page":"1518","volume":"84","author":"A Colao","year":"1999","unstructured":"Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Petretta M, Salvatore M, Lombardi G (1999) Impact of patient\u2019s age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study. J Clin Endocrinol Metab 84:1518\u20131523","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR108","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2265.2002.01476.x","volume":"56","author":"SG Thomas","year":"2002","unstructured":"Thomas SG, Woodhouse LJ, Pagura SM, Ezzat S (2002) Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess. Clin Endocrinol 56:351\u2013358","journal-title":"Clin Endocrinol"},{"key":"797_CR109","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2265.1987.tb02947.x","volume":"27","author":"T Pekkarinen","year":"1987","unstructured":"Pekkarinen T, Partinen M, Pelkonen R, Ivanainen M (1987) Sleep apnoea and daytime sleepiness in acromegaly: relationship to endocrinological factors. Clin Endocrinol 27:649\u2013654","journal-title":"Clin Endocrinol"},{"key":"797_CR110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2265.1995.tb01912.x","volume":"43","author":"L Pelttari","year":"1995","unstructured":"Pelttari L, Polo O, Rauhala E, Vuoriluoto J, Aitasalo K, Hyyppa MT, Kronholm E, Irjala K, Viikari J (1995) Nocturnal breathing abnormalities in acromegaly after adenomectomy. Clin Endocrinol 43:175\u2013182","journal-title":"Clin Endocrinol"},{"key":"797_CR111","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2265.1996.00852.x","volume":"45","author":"F Rosenow","year":"1996","unstructured":"Rosenow F, Reuter S, Deuss U, Szelies B, Hilgers RD, Winkelmann W, Heiss WD (1996) Sleep apnoea in treated acromegaly: relative frequency and predisposing factors. Clin Endocrinol 45:563\u2013569","journal-title":"Clin Endocrinol"},{"key":"797_CR112","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0140-6736(86)91405-4","volume":"1","author":"P Chanson","year":"1986","unstructured":"Chanson P, Timsit J, Benoit O, Augendre B, Moulonguet M, Guillausseau PG, Warnet A, Lubetzki J (1986) Rapid improvement of sleep apnoea of acromegaly after short term treatment with somatostatin analogue SMS 201\u2013995. Lancet 1:1270\u20131271","journal-title":"Lancet"},{"issue":"7","key":"797_CR113","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-121-7-199410010-00002","volume":"121","author":"RR Grunstein","year":"1994","unstructured":"Grunstein RR, Ho KK, Sullivan CE (1994) Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 121(7):478\u2013483","journal-title":"Ann Intern Med"},{"issue":"6","key":"797_CR114","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1530\/EJE-09-0694","volume":"161","author":"C Berg","year":"2009","unstructured":"Berg C, Wessendorf TE, Mortsch F, Forsting M, Teschler H, Weischer T, Mann K, Saller B, Herrmann BL (2009) Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly. Eur J Endocrinol 161(6):829\u2013835","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"797_CR115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/eje.1.02340","volume":"156","author":"L Sze","year":"2007","unstructured":"Sze L, Schmid C, Bloch KE, Bernays R, Br\u00e4ndle M (2007) Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol 156(3):321\u2013329","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"797_CR116","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1210\/jc.2007-2622","volume":"93","author":"E Barrett-Connor","year":"2008","unstructured":"Barrett-Connor E, Dam TT, Stone K, Harrison SL, Redline S, Orwoll E, Osteoporotic Fractures in Men Study Group (2008) The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. J Clin Endocrinol Metab 93(7):2602\u20132609","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR117","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/aja.2011.153","volume":"14","author":"MM Oh","year":"2012","unstructured":"Oh MM, Kim JW, Jin MH, Kim JJ, Moon du G (2012) Influence of paradoxical sleep deprivation and sleep recovery on testosterone level in rats of different ages. Asian J Androl 14:330\u2013334","journal-title":"Asian J Androl"},{"key":"797_CR118","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/jsr.12027","volume":"22","author":"R Killick","year":"2013","unstructured":"Killick R, Wang D, Hoyos CM et al (2013) The effects of testosterone on ventilatory responses in men with obstructive sleep apnoea: a randomised, placebo-controlled trial. J Sleep Res 22:331\u2013336","journal-title":"J Sleep Res"},{"issue":"3","key":"797_CR119","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MED.0000000000000069","volume":"21","author":"G Wittert","year":"2014","unstructured":"Wittert G (2014) The relationship between sleep disorders and testosterone. Curr Opin Endocrinol Diabetes Obes 21(3):239\u2013243","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"797_CR120","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.rmed.2013.08.043","volume":"107","author":"ME Akkoyunlu","year":"2013","unstructured":"Akkoyunlu ME, Ilhan MM, Bayram M, Ta\u015fan E, Yakar F, Oz\u00e7elik HK, Karakose F, Kart L (2013) Does hormonal control obviate positive airway pressure therapy in acromegaly with sleep-disordered breathing? Respir Med 107(11):1803\u20131809","journal-title":"Respir Med"},{"issue":"1","key":"797_CR121","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF03346696","volume":"34","author":"E Menis De","year":"2011","unstructured":"De Menis E, Giustina A, Colao A, Degli Uberti E, Ghigo E, Minuto F, Bogazzi F, Drigo R, Cattaneo A, Aimaretti G, COM.E.T.A. Italian Study Group (2011) Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group. J Endocrinol Invest 34(1):60\u201364","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"797_CR122","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/jc.2009-1912","volume":"95","author":"P Attal","year":"2010","unstructured":"Attal P, Chanson P (2010) Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab 95(2):483\u2013495","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"797_CR123","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-08-0442","volume":"159","author":"MV Davi\u2019","year":"2008","unstructured":"Davi\u2019 MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, Francia, G (2008) Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 159(5):533\u2013540","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"797_CR124","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1183\/13993003.01229-2016","volume":"48","author":"LM Galerneau","year":"2016","unstructured":"Galerneau LM, P\u00e9pin JL, Borel AL, Chabre O, Sapene M, Stach B, Girey-Rannaud J, Arnol N, Tamisier R, Caron P, Scientific council and investigators of the French national sleep apnoea registry (OSFP) (2016) Acromegaly in sleep apnoea patients: a large observational study of 755 patients. Eur Respir J 48(5):1489\u20131492","journal-title":"Eur Respir J"},{"issue":"3","key":"797_CR125","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11102-012-0420-x","volume":"16","author":"S Melmed","year":"2013","unstructured":"Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3):294\u2013302","journal-title":"Pituitary"},{"issue":"1","key":"797_CR126","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11102-013-0471-7","volume":"17","author":"O Alexopoulou","year":"2014","unstructured":"Alexopoulou O, Bex M, Kamenicky P et al (2014) Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17(1):81\u201389","journal-title":"Pituitary"},{"issue":"2","key":"797_CR127","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2265.2009.03626.x","volume":"72","author":"TJ Reid","year":"2010","unstructured":"Reid TJ, Post KD, Bruce JN et al (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol 72(2):203\u2013208","journal-title":"Clin Endocrinol"},{"issue":"2","key":"797_CR128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1530\/EJE-12-0084","volume":"167","author":"M Arosio","year":"2012","unstructured":"Arosio M, Reimondo G, Malchiodi E et al (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167(2):189\u2013198","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"797_CR129","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/A:1023321421760","volume":"5","author":"DR Clemmons","year":"2002","unstructured":"Clemmons DR (2002) Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5(3):181\u2013183","journal-title":"Pituitary"},{"issue":"2","key":"797_CR130","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","volume":"30","author":"N M\u00f8ller","year":"2009","unstructured":"M\u00f8ller N, J\u00f8rgensen JO (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152\u2013177","journal-title":"Endocr Rev"},{"issue":"7","key":"797_CR131","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab 27(7):470\u2013483","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"797_CR132","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000430819","volume":"103","author":"J Dal","year":"2016","unstructured":"Dal J, List EO, J\u00f8rgensen JO, Berryman DE (2016) Glucose and fat metabolism in acromegaly: from mice models to patient care. Neuroendocrinology 103(1):96\u2013105","journal-title":"Neuroendocrinology"},{"key":"797_CR133","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2265.2000.00986.x","volume":"52","author":"S Kasayama","year":"2000","unstructured":"Kasayama S, Otsuki M, Takagi M et al (2000) Impaired-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol 52:549\u2013555","journal-title":"Clin Endocrinol"},{"issue":"6","key":"797_CR134","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/aje\/kwv188","volume":"183","author":"D Drogan","year":"2016","unstructured":"Drogan D, Schulze MB, Boeing H, Pischon T (2016) Insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in relation to the risk of type 2 diabetes mellitus: results from the epic-potsdam study. Am J Epidemiol 183(6):553\u2013560","journal-title":"Am J Epidemiol"},{"key":"797_CR135","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/EJE-10-1050","volume":"164","author":"S Fieffe","year":"2011","unstructured":"Fieffe S, Morange I, Petrossians P et al (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164:877\u2013884","journal-title":"Eur J Endocrinol"},{"key":"797_CR136","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1530\/EC-14-0021","volume":"3","author":"AV Dreval","year":"2014","unstructured":"Dreval AV, Trigolosova IV, Misnikova IV et al (2014) Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect 3:93\u201398","journal-title":"Endocr Connect"},{"issue":"2","key":"797_CR137","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1210\/jc.2008-1546","volume":"94","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Galdiero M et al (2009 Feb) Impact of somatostatin analogues versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 94(2):528\u2013537","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"797_CR138","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1517\/14740338.2015.1059817","volume":"14","author":"LF Grasso","year":"2015","unstructured":"Grasso LF, Auriemma RS, Pivonello R, Colao A (2015) Adverse events associated with somatostatin analogs in acromegaly. Expert Opin Drug Saf 14(8):1213\u20131226","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"797_CR139","first-page":"18","volume":"82","author":"P Caron","year":"1997","unstructured":"Caron P, Morange-Ramos I, Cogne M, Jaquet P (1997) Three year follow up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82(1):18\u201322","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"797_CR140","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"Mazziotti G, Floriani I, Bonadonna S et al (2009) Effects of somatostatin analogues on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94(5):1500\u20131508","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"797_CR141","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-0035-1569277","volume":"48","author":"C Jonas","year":"2016","unstructured":"Jonas C, Maiter D, Alexopoulou O (2016) Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm Metab Res 48(5):299\u2013305","journal-title":"Horm Metab Res"},{"key":"797_CR142","first-page":"82","volume":"8","author":"A Valea","year":"2015","unstructured":"Valea A, Carsote M, Ghervan C, Georgescu C (2015) Glycemic profile in patients with acromegaly treated with somatostatin analogue. J Med Life 8 Spec Issue:82\u201386","journal-title":"J Med Life"},{"issue":"1","key":"797_CR143","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00024677-200504010-00005","volume":"4","author":"AM Pereira","year":"2005","unstructured":"Pereira AM, Biermasz NR, Roelfsema F, Romijn JA (2005) Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treat Endocrinol 4(1):43\u201353","journal-title":"Treat Endocrinol"},{"issue":"3","key":"797_CR144","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1530\/EJE-10-0811","volume":"164","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Porcelli T, Bogazzi F et al (2011 Mar) Effect of high dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 164(3):341\u2013347","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"797_CR145","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P et al (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99(3):791\u2013799","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"797_CR146","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2265.1992.tb01443.x","volume":"36","author":"KK Ho","year":"1992","unstructured":"Ho KK, Jenkins AB, Furler SM et al (1992) Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol 36(3):271\u2013279","journal-title":"Clin Endocrinol"},{"issue":"1","key":"797_CR147","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11102-011-0318-z","volume":"15","author":"A Colao","year":"2012","unstructured":"Colao A (2012) Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 15(1):50\u201358","journal-title":"Pituitary"},{"issue":"7","key":"797_CR148","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1210\/jc.2008-2086","volume":"94","author":"CE Higham","year":"2009","unstructured":"Higham CE, Rowles S, Russell-Jones D et al (2009) Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab 94(7):2459\u20132463","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR149","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/EJE-10-1096","volume":"164","author":"Y Kinoshita","year":"2011","unstructured":"Kinoshita Y et al (2011) Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery in pancreatic b-cell function is preserved. Eur J Endocrinol 164:467\u2013473","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"797_CR150","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1210\/jc.2006-1578","volume":"92","author":"V Singh","year":"2007","unstructured":"Singh V, Brendel MD, Zacharias S et al (2007) Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 92(2):673\u2013680","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR151","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/B978-0-12-800174-5.00007-7","volume":"95","author":"M Braun","year":"2014","unstructured":"Braun M (2014) The somatostatin receptor in human pancreatic \u03b2-cells. Vitam Horm 95:165\u2013193","journal-title":"Vitam Horm"},{"issue":"25","key":"797_CR152","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJM198512193132504","volume":"313","author":"SW Lamberts","year":"1985","unstructured":"Lamberts SW, Uitterlinden P, Verschoor L et al (1985) Long-term treatment of acromegaly with the somatostatin analogue SMS 201\u2013995. N Engl J Med 313(25):1576\u20131580","journal-title":"N Engl J Med"},{"issue":"5","key":"797_CR153","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-2007-979945","volume":"27","author":"M Breidert","year":"1995","unstructured":"Breidert M, Pinzer T, Wildbrett J et al (1995) Long-term effect of octreotide in acromegaly on insulin resistance. Horm Metab Res 27(5):226\u2013230","journal-title":"Horm Metab Res"},{"issue":"1","key":"797_CR154","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2005-1704","volume":"91","author":"CL Ronchi","year":"2006","unstructured":"Ronchi CL, Varca V, Beck-Peccoz P et al (2006) Comparison between six-year therapy with long-acting somatostatin analogues and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91(1):121\u2013128","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"797_CR155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1530\/eje.1.02185","volume":"155","author":"B Steffin","year":"2006","unstructured":"Steffin B, Gutt B, Bidlingmaier M et al (2006) Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 155(1):73\u201378","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"797_CR156","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446\u20133453","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"797_CR157","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0006-2952(99)00010-6","volume":"57","author":"Y Zambre","year":"1999","unstructured":"Zambre Y, Ling Z, Chen MC, Hou X et al (1999) Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol 57(10):1159\u20131164","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"797_CR158","doi-asserted-by":"crossref","first-page":"E311","DOI":"10.1152\/ajpendo.00434.2001","volume":"283","author":"C Chisholm","year":"2002","unstructured":"Chisholm C, Greenberg GR (2002) Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. Am J Physiol Endocrinol Metab 283(2):E311\u2013E317","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"797_CR159","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controller acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875\u2013884","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"797_CR160","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1517\/13543784.2013.805201","volume":"22","author":"LF Grasso","year":"2013","unstructured":"Grasso LF, Pivonello R, Colao A (2013) Investigational therapies for acromegaly. Expert Opin Investig Drugs 22(8):955\u2013963","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"797_CR161","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","volume":"53","author":"HA Schmid","year":"2016","unstructured":"Schmid HA, Brue T, Colao A et al (2016) Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocr 53(1):210\u2013219","journal-title":"Endocr"},{"key":"797_CR162","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/eje.1.02312","volume":"156","author":"I Schreiber","year":"2007","unstructured":"Schreiber I, Buchfelder M, Droste M et al (2007) Treatment of acromegaly with the GH receptor antagonist Pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75\u201382","journal-title":"Eur J Endocrinol"},{"key":"797_CR163","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1530\/eje.0.1490521","volume":"149","author":"WM Drake","year":"2003","unstructured":"Drake WM, Rowles SV, Roberts ME et al (2003) Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to Pegvisomant. Eur J Endocrinol 149:521\u2013527","journal-title":"Eur J Endocrinol"},{"key":"797_CR164","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","volume":"90","author":"AL Barkan","year":"2005","unstructured":"Barkan AL, Burman P, Clemmons DR et al (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to Pegvisomant. J Clin Endocrinol Metab 90:5684\u20135691","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR165","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/BF03345774","volume":"32","author":"E Ghigo","year":"2009","unstructured":"Ghigo E, Biller BM, Colao A et al (2009) Comparison of Pegvisomant and long-acting octreotide in patients with acromegaly na\u00efve to radiation and medical therapy. J Endocrinol Invest 32:924\u2013933","journal-title":"J Endocrinol Invest"},{"key":"797_CR166","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1210\/jc.2006-2276","volume":"92","author":"R Lindberg-Larsen","year":"2007","unstructured":"Lindberg-Larsen R, M\u00f8ller N, Schmitz O et al (2007) The impact of Pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724\u20131728","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR167","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1210\/jc.2008-2086","volume":"94","author":"CE Higham","year":"2009","unstructured":"Higham CE, Rowles S, Russell-Jones D et al (2009) Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab 94:2459\u20132463","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR168","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1096-6374(02)00083-7","volume":"12","author":"DR Rose","year":"2002","unstructured":"Rose DR, Clemmons DR (2002) Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 12:418\u2013424","journal-title":"Growth Horm IGF Res"},{"key":"797_CR169","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","volume":"71","author":"PJ Trainer","year":"2009","unstructured":"Trainer PJ, Ezzat S, D\u2019Souza GA et al (2009) A randomized, controlled, multicentre trial comparing Pegvisomant alone with combination therapy of Pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol 71:549\u2013557","journal-title":"Clin Endocrinol"},{"issue":"11","key":"797_CR170","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1210\/jc.2009-0381","volume":"94","author":"L Moller","year":"2009","unstructured":"Moller L, Norrelund H, Jessen N et al (2009) Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects. J Clin Endocrinol Metab 94(11):4524\u20134532","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"797_CR171","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/EJE-10-1170","volume":"164","author":"NE Kokshoorn","year":"2011","unstructured":"Kokshoorn NE, Biermasz NR, Roelfsema F et al (2011) GH replacement therapy in elderly GH-deficient patients: a systematic review. Eur J Endocrinol 164(5):657\u2013665","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"797_CR172","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11102-010-0281-0","volume":"14","author":"PW Rosario","year":"2011","unstructured":"Rosario PW (2011) Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population. Pituitary 14(3):217\u2013221","journal-title":"Pituitary"},{"key":"797_CR173","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0029-1211774","volume":"105","author":"J Wildbrett","year":"1997","unstructured":"Wildbrett J, Hanefeld M, Fucker K et al (1997) Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin\u2013like growth factor I. Exp Clin Endocrinol Diabetes 105:331\u2013335","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"797_CR174","unstructured":"Linton MF, Yancey PG, Davies SS, Jerome WGJ, Linton EF, Vickers KC (2000\u20132015) The role of lipids and lipoproteins in atherosclerosis. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A (eds) Source Endotext [Internet]. MDText.com, Inc., South Dartmouth"},{"issue":"2","key":"797_CR175","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12020-013-9904-3","volume":"44","author":"VE Chaves","year":"2013","unstructured":"Chaves VE, J\u00fanior FM, Bertolini GL (2013) The metabolic effects of growth hormone in adipose tissue. Endocr 44(2):293\u2013302","journal-title":"Endocr"},{"key":"797_CR176","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0021-9150(00)00433-0","volume":"153","author":"JA Beentjes","year":"2000","unstructured":"Beentjes JA, van Tol A, Sluiter WJ, Dullaart RP (2000) Low plasma lecithin: cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis 153:491\u2013498","journal-title":"Atherosclerosis"},{"issue":"2","key":"797_CR177","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2265.2008.03181.x","volume":"69","author":"SP Delaroudis","year":"2008","unstructured":"Delaroudis SP, Efstathiadou ZA, Koukoulis GN et al (2008) Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol 69(2):279\u2013284","journal-title":"Clin Endocrinol"},{"issue":"10","key":"797_CR178","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40618-014-0146-x","volume":"37","author":"A Giustina","year":"2014","unstructured":"Giustina A, Ambrosio MR, Beck Peccoz P et al (2014) Use of pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest 37(10):1017\u20131030","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"797_CR179","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2265.2002.01460.x","volume":"56","author":"C Parkinson","year":"2002","unstructured":"Parkinson C, Drake WM, Wieringa G et al (2002) Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol 56(3): 303\u2013311","journal-title":"Clin Endocrinol"},{"issue":"4","key":"797_CR180","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","volume":"87","author":"G Sesmilo","year":"2002","unstructured":"Sesmilo G, Fairfield WP, Katznelson L et al (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87(4):1692\u20131699","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR181","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1210\/jc.2009-2570","volume":"95","author":"C Berg","year":"2010","unstructured":"Berg C, Petersenn S, Lahner H et al (2010) Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 2010;95:3648\u20133656","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR182","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/ncpendmet0831","volume":"4","author":"I Hodish","year":"2008","unstructured":"Hodish I, Barkan A (2008) Long-term effects of Pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 4:324\u2013332","journal-title":"Nat Clin Pract Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-017-0797-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-017-0797-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-017-0797-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T19:00:05Z","timestamp":1568833205000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-017-0797-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":182,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s11102-017-0797-7","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}